Photobiomodulation (light therapy) for amnestic mild cognitive impairment (aMCI)
What is the study about?
This study is looking at using a form of non-invasive light therapy called photobiomodulation as a treatment for amnestic Mild Cognitive Impairment (aMCI), which is an early stage of Alzheimer’s disease. The study will look at the effect of the light therapy on your thinking abilities, quality of life, and the powerhouse of cells (the mitochondria).
Eligibility- Who can participate?
Participants must:
- Be 50 years of age or older
- Have a diagnosis of Mild Cognitive Impairment (MCI)
Time requirement
The entire study can take 10 to 12 weeks, and consist of:
- Screening visit to assess eligibility
- Baseline visit (2-3 sessions) to complete cognitive testing, blood test, and brain MRI/MRS
- At home treatments for 20 minutes per day, 6 days a week, for 6 weeks
- Post treatment visit (2-3 sessions) to complete the same tasks as the baseline visit
Study Video
Advances in Dementia Research Webinar- Listen to Dr. Neda Rashidi-Ranjbar discuss this study in further detail:
Do you have questions about research studies you saw on this page?
Please contact tdra@utoronto.ca
Disclaimer
The listing of a study on the TDRA’s Research Studies Portal is for informational purposes only. The safety, efficacy or scientific validity of the studies listed here have not been evaluated by The Alzheimer Society of Toronto (AST) or the Toronto Dementia Research Alliance (TDRA). The TDRA is an academic coalition among the University of Toronto and Baycrest, the Centre for Addiction and Mental Health, Ontario Shores Centre for Mental Health Sciences, Sunnybrook Health Sciences Centre, and the University Health Network. The information collected will be kept and guarded by TDRA. Choosing to participate in a study is an important personal decision. Before you participate in a study, you should make sure you understand the risks and potential benefits and discuss all options with your health care provider(s).